 |
 |
|
| Startseite |
| Impressum |
| Datenschutz |
 | |
| Volume 38, 15 June 2007 | 6/2007 |
| SPOT ON | |
Will the ban on direct-to-consumer-advertising ("DTCA") for prescription drugs be lifted? | |
| NEW ON THE MARKET | |
New oral antidiabetic: DPP-IV-inhibitor Sitagliptin (JANUVIA) | |
| THERAPY FROM A CRITICAL VIEWPOINT | |
HPV-vaccine GARDASIL: benefit overestimated? | |
 |
Memantine (AXURA, EBIXA) for ALZHEIMER disease: negative results suppressed |
| BEWARE MISINFORMATION | |
"M2-PK" - no outmatching screening marker for colonic cancer | |
| QUALITY CONTROL | |
Amitriptyline-preparations (SAROTEN TABS u.a.): good qualitiy | |
| IN BRIEF | |
Elsevier: publisher for medical literature retires from business with weapons | |
| CURRENT ADR NETWORK REPORT | |
Facial edemas due to anti-obesity drug rimonabant (ACOMPLIA) | |
| SIDE EFFECTS | |
Antidiabetic rosiglitazone (AVANDIA): suspicion of cardiotoxicity aggravated | |
|
© arznei-telegramm 6/2007 | ||
 |  | |